ClinicalTrials.Veeva

Menu

Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C

National Institute of Allergy and Infectious Diseases (NIAID) logo

National Institute of Allergy and Infectious Diseases (NIAID)

Status

Completed

Conditions

Liver Transplantation

Study type

Observational

Funder types

NETWORK
NIH

Identifiers

NCT01428700
DAIT CTOT-07

Details and patient eligibility

About

Acute cellular rejection is relatively common after liver transplantation, typically does not affect graft survival, and is not associated with the development of chronic rejection. Acute cellular rejection is diagnosed when liver enzymes and/or liver function tests are elevated when compared to baseline. The only means of differentiating acute rejection from other liver pathologies is with a liver biopsy. However, even with this invasive diagnostic procedure, it may be difficult to distinguish acute rejection from another disease process, such as injury caused by the hepatitis C virus (HCV) from the native liver. This study will evaluate whether certain patterns of biomarkers in the peripheral blood and/or liver tissue of a liver transplant recipient can be used to determine if the transplanted liver is being rejected by the recipient or sustaining HCV injury. Diagnostic biomarkers that are specific for acute rejection and informative of the severity of HCV recurrence could allow for modulation of immunosuppression therapy and treat the clinical condition without the need for invasive liver biopsies.

Enrollment

275 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Specimens derived from subjects enrolled in the ITN030ST study.
  • Availability of adequate biopsy specimens with corresponding blood and/or serum collected within a 10 day window of a for-cause or protocol biopsy.

Exclusion criteria

  • Withdrawal of consent for the ITN030ST study.
  • Absence of consent in the ITN030ST study for the collection and storage of samples of blood and tissue for future research studies.

Trial design

275 participants in 2 patient groups

Non-Immune/Non-Viral (NINV)
Description:
Patients enrolled in ITN030ST transplanted for liver failure resulting from non-viral, non-immune causes
Hepatitis C Virus (HCV) positive
Description:
Patients enrolled in ITN030ST transplanted for liver failure resulting from HCV genotype 1 infection

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems